Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Market Size of the Candidiasis Therapeutics Market In 2029?
The market size for therapeutics treating candidiasis has seen consistent enlargement in past years. Projected to expand from $3.19 billion in 2024 to $3.29 billion in 2025, the market is expected to experience a compound annual growth rate (CAGR) of 3.0%. The growth observed in the historic timeframe is associated with a rise in candidiasis occurrence, the use and resistance of antibiotics, infections acquired from hospitals, changes in patterns of fungal resistance, along with educational programs and awareness efforts.
In the coming years, the candidiasis therapeutics market is anticipated to witness consistent growth, reaching $” 3.83 billion in 2029 with a compound annual growth rate (CAGR) of 3.9%. The growth within the forecasted period can be attributed to the integration of precision medicine approaches, global efforts to tackle antifungal resistance, growing incidences of candida auris, and antifungal stewardship programs being implemented globally. Further, advancements in drug delivery technologies, the use of telemedicine and remote patient monitoring, emphasis on patient-centric care, combination therapies, and collaborative research initiatives are the major trends expected in this forecast period.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13182&type=smp
Which Factors and External Forces Are Driving Demand in the Candidiasis Therapeutics Market?
The escalation in instances of fungal diseases is predicted to boost the expansion of the candidiasis therapeutics market in future. Diseases triggered by diverse fungi that can harm the skin, mucous membranes, and internal organs in humans are classified as fungal infections. The increase in the number of people with weakened immune systems and those suffering from fungal infections heightens the vulnerability to candidiasis. This presents opportunities for manufacturers to design and supply specialized and more efficacious antifungal medicines that specifically target the root fungal pathogens. These medications aim to alleviate symptoms, prevent complications, aid patient recovery, limit the dissemination of Candida infections within healthcare establishments and contribute to improved patient outcomes. For example, based on data from the University of Minnesota, a research university based in the US, in January 2024, fungal diseases contributed to over 3.75 million deaths every year, with roughly 2.55 million of these fatalities directly linked to fungal ailments. Consequently, the increasing prevalence of fungal infections is anticipated to stimulate the growth of the candidiasis therapeutics market.
Which Segments in the Candidiasis Therapeutics Offer the Most Growth?
The candidiasis therapeuticsmarket covered in this report is segmented –
1) By Treatment Type: Medication; Surgery; Other Treatments
2) By Anatomy Type: Oral Candidiasis; Vulvovaginal Candidiasis; Cutaneous Candidiasis; Invasive Candidiasis; Systemic Candidiasis
3) By Mode Of Administration: Injectable; Oral; Other Mode Of Administrations
4) By Patient Population: Adults; Pediatrics
5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Medication: Antifungal Drugs; Topical Treatments; Systemic Treatments
2) By Surgery: Surgical Debridement; Organ Removal
3) By Other Treatments: Probiotics; Home Remedies; Lifestyle Modifications
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13182&type=smp
What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Candidiasis Therapeutics Market?# Market?
North America was the largest region in the candidiasis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the candidiasis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Which Cutting-Edge Market Trends Are Expected to Drive theCandidiasis Therapeutics Market’s Growth?
Primarily, firms operating within the candidiasis therapeutics market are concentrating on creating ground-breaking medications like BREXAFEMME (ibrexafungerp tablets) in an effort to lessen the recurrence rate of RVVC in adult females. BREXAFEMME (ibrexafungerp tablets) is a non-azole oral drug utilized in treating vulvovaginal candidiasis (VVC) and in lessening the rate of recurrent RVVC, popularly known as chronic yeast infections. For instance, in December 2022, the US pharmaceutical firm Scynexis Inc. was given approval by the US Food and Drug Administration to use BREXAFEMME (ibrexafungerp tablets) in treating vulvovaginal candidiasis (VVC) and in decreasing the recurrent episodes of RVVC, another name for chronic yeast infections. The way BREXAFEMME works is by stunting the growth of the Candida albicans fungus, which is responsible for VVC. Additionally, it’s a safe and efficient treatment choice for vulvovaginal candidiasis (VVC) and accessible solely through a prescription, with the advised dosage being one 150-mg capsule to be taken orally once per day for a day.
View the full report here:
https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-market-report
What Are the Key Elements That Define the Candidiasis Therapeutics Market?
Candidiasis is a fungal infection caused by the overgrowth of Candida species that naturally reside in the human body, particularly in the mouth, throat, gut, and genital area. Treatment for candidiasis typically involves antifungal medications, which can be topical (applied to the affected area) or oral (taken by mouth), depending on the severity and location of the infection.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13182
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model